WASHINGTON, June 16 -- National Institutes of Health has issued a notice called: Government Owned Inventions Available for License: Establishment and Characterization of the A1847 Human Ovarian Carcinoma Line.
The notice was published in the Federal Register on June 16 by Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute.
Summary: The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a patient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage.
For more information, contact Inquiries related to this license...